Loading...
MLTX logo

MoonLake ImmunotherapeuticsNasdaqCM:MLTX Stock Report

Market Cap US$1.5b
Share Price
n/a
1Y-58.1%
7D3.6%
1D-0.5%
Portfolio Value
​
View

MoonLake Immunotherapeutics

NasdaqCM:MLTX Stock Report

Market Cap: US$1.5b

MoonLake Immunotherapeutics (MLTX) Stock Overview

A clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. More details

MLTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 63.96% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


MLTX Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

MoonLake Immunotherapeutics Competitors

Price History & Performance

Summary of share price highs, lows and changes for MoonLake Immunotherapeutics
Historical stock prices
Current Share PriceUS$19.90
52 Week HighUS$62.75
52 Week LowUS$5.95
Beta1.04
1 Month Change8.09%
3 Month Change14.90%
1 Year Change-58.12%
3 Year Change-60.98%
5 Year Change95.10%
Change since IPO89.70%

Recent News & Updates

Recent updates

Analysis Article • Jul 26

Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jun 03

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Summary MoonLake Immunotherapeutics completed enrollment in the two-phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights the significant buyout potential of the company and validates its late-stage pipeline value. MLTX's strong cash position funds operations into 2028, but risks remain around clinical trial outcomes and competitive benchmarks, especially versus SKYRIZI in PsA. Read the full article on Seeking Alpha
Analysis Article • Apr 09

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 08

MoonLake Immunotherapeutics: A Buy At Dips

Summary MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed results from the ARGO study, sonelokimab demonstrated superior efficacy against Humira and Secukinumab, indicating strong potential for future success. Institutional sell-offs in late 2023 caused a drastic stock decline, but MLTX remains financially stable with a cash runway extending into 2027. With promising catalysts in 2025 and potential market opportunities worth billions, MLTX is a buy on dips for risk-tolerant investors. Read the full article on Seeking Alpha
Analysis Article • Jan 20

Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, MoonLake Immunotherapeutics fair value estimate is US$72.37...
Analysis Article • Dec 16

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 13

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold

Summary MoonLake Immunotherapeutics' stock has been volatile but is currently back to its previous year's level, reflecting mixed performance in a bullish biotech market. SLK, MoonLake's key asset, shows promising Phase 2b results in HS, PsA, and psoriasis, with Phase 3 trials ongoing and new indications being explored. Financially, MLTX has a $3bn market cap and $520mn cash, ensuring a runway of 10-12 quarters despite significant R&D expenses. The primary risk is the lack of near-term catalysts, with significant data expected only by mid-2025, making it a hold rather than a buy. Read the full article on Seeking Alpha
Analysis Article • Aug 27

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jul 18

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

Summary MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026. There is potential to establish a competitive advantage by using Nanobody technology, which incorporates smaller molecules along with drugs developed to target both cytokines IL-17A and IL-17F. Read the full article on Seeking Alpha
Analysis Article • May 14

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Feb 26

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Summary MoonLake Immunotherapeutics has exclusively licensed nanobody technology to develop treatments for inflammatory diseases. The company is focusing on psoriasis and hidradenitis suppurativa, targeting interleukins 17A and 17F as the main culprits for excessive inflammation. MoonLake has completed phase 2 clinical trials and is entering phase 3, showing promising results so far, but there are still development risks and outstanding financial burdens. The value gap exists, which is positive, but with the development risks of a novel technology, we aren't sure what sort of margin of safety can be expected. Read the full article on Seeking Alpha
Analysis Article • Jan 29

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 16

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, MoonLake...
Seeking Alpha • Jul 26

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX) on Tuesday said it had signed a services agreement with contract development and manufacturing organization Vetter Pharma International GmbH. As per the deal, Vetter will be responsible for fill and finish services. Vetter will oversee the the aseptic filling of syringes with MLTX's investigational nanobody sonelokimab. Vetter will also be responsible for the subsequent assembly into an autoinjector combination device and packaging. MLTX stock -1.8% to $6.93 in morning trading.

Shareholder Returns

MLTXUS BiotechsUS Market
7D3.6%5.1%-2.7%
1Y-58.1%36.7%18.6%

Return vs Industry: MLTX underperformed the US Biotechs industry which returned 36.7% over the past year.

Return vs Market: MLTX underperformed the US Market which returned 18.6% over the past year.

Price Volatility

Is MLTX's price volatile compared to industry and market?
MLTX volatility
MLTX Average Weekly Movement10.1%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: MLTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MLTX's weekly volatility has decreased from 17% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2021130Jorge da Silvawww.moonlaketx.com

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics Fundamentals Summary

How do MoonLake Immunotherapeutics's earnings and revenue compare to its market cap?
MLTX fundamental statistics
Market capUS$1.47b
Earnings (TTM)-US$257.08m
Revenue (TTM)n/a
0.0x
P/S Ratio
-5.7x
P/E Ratio

Is MLTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MLTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$257.08m
Earnings-US$257.08m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-3.49
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio39.0%

How did MLTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 22:22
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MoonLake Immunotherapeutics is covered by 15 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Prakhar AgrawalCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc